DOACs versus aspirin for secondary prevention of stroke after ESUS: an updated systematic review and meta-analysis of randomized clinical trials
Circulation; 150 (Suppl. 1), 2024
BACKGROUND: Embolic stroke of undetermined source (ESUS) is a nonlacunar ischemic stroke with no clear cause, having a 4%-5% annual recurrence rate. The potential benefits of direct oral anticoagulants (DOACs) relative to aspirin in patients with ESUS remain unclear. OBJECTIVE: We aimed to perform a syst...